Semaglutide vs Tirzepatide vs Retatrutide: Single, Dual, and Triple Agonists
By Lemon Labs Research Desk · Updated June 29, 2026
In short
The cleanest way to understand these three research peptides is by how many receptors each engages: semaglutide is a single agonist (GLP-1), tirzepatide is a dual agonist (GIP + GLP-1), and retatrutide is a triple agonist (GIP + GLP-1 + glucagon). That escalating receptor count is the central variable researchers compare. All three are research-use-only reference compounds.
One framework: count the receptors
These three peptides are best understood as a progression in incretin pharmacology. Semaglutide engages one receptor, tirzepatide two, and retatrutide three. Each added receptor introduces a new signaling pathway researchers can study.
- Semaglutide — single agonist: GLP-1 receptor only.
- Tirzepatide — dual agonist: GIP + GLP-1 receptors.
- Retatrutide — triple agonist: GIP + GLP-1 + glucagon receptors.
What each added receptor contributes
The GLP-1 receptor is the foundation, associated in research with glucose-dependent insulin signaling. Adding the GIP receptor (tirzepatide) introduces a second incretin pathway. Adding the glucagon receptor (retatrutide) brings in glucagon signaling, which research links to energy-expenditure pathways — a mechanistically distinct addition to incretin agonism.
Why researchers line them up
Because they share a common GLP-1 foundation and differ by defined receptor additions, these three peptides form a natural comparison set in receptor-pharmacology and signaling research. Semaglutide often serves as the single-agonist reference point against which the multi-agonists are characterized in binding and cAMP-signaling assays.
Structure and handling
All three are synthetic peptides with half-life-extending modifications, supplied lyophilized and characterized by HPLC and mass spectrometry. Store cold and sealed, protected from light, and verify ≥99% purity and identity on each lot-specific COA.
Research-use-only statement
This compound is supplied strictly for in-vitro research and laboratory use. It is not a drug, supplement, food, or cosmetic, has not been evaluated by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or veterinary use. All information here summarizes published scientific literature for educational purposes for qualified researchers — it is not medical advice and does not describe human administration.
Reference compounds mentioned
Frequently asked
What is the difference between semaglutide, tirzepatide, and retatrutide?
They differ by receptor count: semaglutide is a single GLP-1 agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide is a triple GIP/GLP-1/glucagon agonist.
Which one targets the most receptors?
Retatrutide, a triple agonist engaging the GIP, GLP-1, and glucagon receptors.
What does the glucagon receptor add in retatrutide?
Glucagon-receptor agonism introduces glucagon signaling, which research associates with energy-expenditure pathways — a mechanism distinct from the incretin (GIP/GLP-1) activity shared by all three.
Are these for human use?
No. All three are research-use-only reference compounds, not for human or veterinary use.